<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "pertuzumab inj VIAL">
<dose><value>840</value>
<value>420</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>pertuzumab inj VIAL</value>
</drugname><strength><value>30 mg/mL</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>Administer dose diluted in 250 mL 0.9% sodium chloride over 60 minutes.</value>
<value>Administer dose diluted in 250 mL 0.9% sodium chloride over 30 to 60 minutes.</value>
</instruction><volume><value>14 mL</value>
</volume><units><value>mg</value>
</units><additionalnotes><value>Metastatic Breast Cancer. Observe patient for a 60 minute period post-infusion.</value>
<value>Metastatic Breast Cancer. Observe patient for a 30 minute period post-infusion. If the time between infusions is less than 6 weeks, the 420 mg dose may be continued. If the time between infusions is 6 weeks or more, a dose of 840 mg pertuzumab should be re-administered and then subsequent dosing would continue at 420 mg.</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6322</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>